Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANEBNASDAQ:AVTXNASDAQ:CNTBNASDAQ:DWTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$1.12+0.9%$1.15$0.80▼$3.08$46.02M-1.1218,532 shs4,279 shsAVTXAvalo Therapeutics$3.75-4.1%$5.41$3.39▼$16.00$40.61M0.8753,951 shs29,521 shsCNTBConnect Biopharma$0.76-8.4%$0.74$0.51▼$2.07$41.79M-0.356,257 shs84,790 shsDWTXDogwood Therapeutics$5.24-1.1%$4.90$1.62▼$29.28$10.01M1.981.77 million shs66,702 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals+0.90%+9.80%+15.46%-11.11%-46.67%AVTXAvalo Therapeutics-4.09%-4.09%-24.24%-55.57%-65.25%CNTBConnect Biopharma-8.37%+0.53%+11.03%-13.23%-55.59%DWTXDogwood Therapeutics-1.13%-1.50%-10.73%-2.60%+523,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANEBAnebulo Pharmaceuticals2.2965 of 5 stars3.55.00.00.01.01.70.0AVTXAvalo Therapeutics3.3921 of 5 stars4.45.00.00.00.01.71.3CNTBConnect Biopharma2.7447 of 5 stars3.55.00.00.00.62.50.6DWTXDogwood Therapeutics1.1903 of 5 stars3.50.00.00.00.70.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANEBAnebulo Pharmaceuticals 3.00Buy$5.50391.07% UpsideAVTXAvalo Therapeutics 2.83Moderate Buy$33.00780.00% UpsideCNTBConnect Biopharma 3.00Buy$8.00959.60% UpsideDWTXDogwood Therapeutics 3.00Buy$10.0090.84% UpsideCurrent Analyst Ratings BreakdownLatest DWTX, ANEB, CNTB, and AVTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025ANEBAnebulo PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $3.004/23/2025DWTXDogwood TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$10.003/31/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/25/2025AVTXAvalo TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform ➝ Buy$23.003/25/2025AVTXAvalo TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$36.003/20/2025AVTXAvalo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/20/2025AVTXAvalo TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$18.002/28/2025AVTXAvalo TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$48.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.15 per shareN/AAVTXAvalo Therapeutics$441K92.07N/AN/A$9.11 per share0.41CNTBConnect Biopharma$26.03M1.61N/AN/A$1.83 per share0.41DWTXDogwood TherapeuticsN/AN/AN/AN/A$4.94 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANEBAnebulo Pharmaceuticals-$8.20M-$0.26N/A∞N/AN/A-119.54%-108.08%N/AAVTXAvalo Therapeutics-$31.54MN/A0.00N/AN/AN/A-442.16%122.99%8/11/2025 (Estimated)CNTBConnect Biopharma-$59.50MN/A0.00N/AN/AN/AN/AN/AN/ADWTXDogwood Therapeutics-$5.30M-$18.04N/AN/AN/AN/A-217.12%-172.06%N/ALatest DWTX, ANEB, CNTB, and AVTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CNTBConnect Biopharma-$0.26-$0.19+$0.07-$0.19N/AN/A5/13/2025Q3 2025ANEBAnebulo Pharmaceuticals-$0.05-$0.04+$0.01-$0.04N/AN/A5/12/2025Q1 2025AVTXAvalo Therapeutics-$1.07-$1.25-$0.18-$1.25N/AN/A5/8/2025Q1 2025DWTXDogwood Therapeutics-$0.77-$4.21-$3.44-$8.45N/AN/A3/31/2025Q4 2024DWTXDogwood Therapeutics-$1.49-$6.29-$4.80-$6.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/AAVTXAvalo TherapeuticsN/AN/AN/AN/AN/ACNTBConnect BiopharmaN/AN/AN/AN/AN/ADWTXDogwood TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANEBAnebulo PharmaceuticalsN/A17.5117.51AVTXAvalo TherapeuticsN/A1.421.42CNTBConnect BiopharmaN/A12.04N/ADWTXDogwood TherapeuticsN/A1.711.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANEBAnebulo Pharmaceuticals28.40%AVTXAvalo Therapeutics87.06%CNTBConnect Biopharma58.72%DWTXDogwood Therapeutics9.05%Insider OwnershipCompanyInsider OwnershipANEBAnebulo Pharmaceuticals80.60%AVTXAvalo Therapeutics3.03%CNTBConnect Biopharma22.60%DWTXDogwood Therapeutics3.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANEBAnebulo Pharmaceuticals441.09 million5.79 millionNot OptionableAVTXAvalo Therapeutics4010.83 million10.37 millionNot OptionableCNTBConnect Biopharma11055.35 million42.77 millionOptionableDWTXDogwood Therapeutics51.91 million1.17 millionN/ADWTX, ANEB, CNTB, and AVTX HeadlinesRecent News About These CompaniesZacks Small Cap Has Bearish Forecast for DWTX Q2 EarningsMay 17, 2025 | americanbankingnews.comDWTX: Phase 2b Trial in Chemotherapy Induced Neuropathic Pain Underway…May 14, 2025 | finance.yahoo.comDogwood Therapeutics Stock Short Interest Report | NASDAQ:DWTX | BenzingaMay 9, 2025 | benzinga.comDogwood Therapeutics Announces First Quarter 2025 Financial ResultsMay 8, 2025 | finance.yahoo.comDogwood Therapeutics Announces First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comDogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global ConferenceMay 1, 2025 | newsfilecorp.comHC Wainwright & Co. Upgrades Dogwood Therapeutics (DWTX)April 24, 2025 | msn.comDogwood receives Nasdaq confirmation of complianceApril 11, 2025 | markets.businessinsider.comDogwood Therapeutics, Inc. Receives Nasdaq Confirmation of ComplianceApril 11, 2025 | financialpost.comDogwood Therapeutics, Inc. Receives Nasdaq Confirmation of ComplianceApril 11, 2025 | globenewswire.comDogwood management to meet with MaximApril 9, 2025 | markets.businessinsider.comDWTX: Interim Data for Phase 2b Trial in 4Q25…April 5, 2025 | msn.comDogwood regains Nasdaq complianceApril 4, 2025 | markets.businessinsider.comDogwood Therapeutics, Inc. Regains Nasdaq ComplianceApril 3, 2025 | globenewswire.comDogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial ResultsMarch 31, 2025 | globenewswire.comDogwood doses first patient in Phase 2b trial of HalneuronMarch 18, 2025 | markets.businessinsider.comDWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP; Debt Conversion Strengthens Balance Sheet…March 18, 2025 | msn.comDogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic PainMarch 18, 2025 | globenewswire.comMaxim Group Remains a Buy on Dogwood Therapeutics (DWTX)March 13, 2025 | markets.businessinsider.comDogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesMarch 13, 2025 | financialpost.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDWTX, ANEB, CNTB, and AVTX Company DescriptionsAnebulo Pharmaceuticals NASDAQ:ANEB$1.12 +0.01 (+0.90%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.12 0.00 (0.00%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Avalo Therapeutics NASDAQ:AVTX$3.75 -0.16 (-4.09%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$3.94 +0.19 (+5.07%) As of 05/23/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Connect Biopharma NASDAQ:CNTB$0.76 -0.07 (-8.37%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$0.77 +0.02 (+1.99%) As of 05/23/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.Dogwood Therapeutics NASDAQ:DWTX$5.24 -0.06 (-1.13%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$5.20 -0.04 (-0.76%) As of 05/23/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
